Shortening the duration of therapy for chronic hepatitis C infection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28802815.
- Also identified by DOI 10.1016/S2468-1253(17)30053-5 and PMC identifier 5737004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination direct-acting antiviral therapy of 8-24 weeks is highly effective for the treatment of chronic hepatitis C infection. However, shortening the treatment duration to less than 8 weeks could potentially reduce overall treatment costs and improve adherence. Here we explore the arguments for and against the development of short-duration regimens and existing data on treatment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection. Additionally, we identify potential predictors of response to short-course combination therapies with direct-acting antiviral drugs that might be explored in future clinical trials.
Medical subject headings
- Antiviral Agents
- Hepatitis C, Chronic